Medication info
Amlobika HCT Tablet 5/20/12.5 Milligrams

Amlobika HCT Tablet 5/20/12.5 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Dongkook Pharmaceutical Co., Ltd.
Appearance
White-orange round film-coated tablet
Packaging
28 Tablets (14 Tablets/PTP * 2)
Approval status
Active

MFDS item code 201805284 · Approved 2018.12.26 · Insurance code 653404270

Summary

Main use
Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. It is recommended that you take it at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dosage be adjusted using the individual ingredients (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose escalation schedule. (The content of each ingredient is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment For patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min), the maximum dose of this medicine is 20/5/12.5mg once daily. Monitoring potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. For patients with moderate hepatic impairment, the maximum dose of this medicine is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Elderly patients (65 years and older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. Blood pressure should be monitored closely and more frequently in elderly patients. Since experience with the use of this medicine in elderly patients, particularly those aged 75 years and older, is very limited, monitor very carefully when administering this medicine.
Child dose
Safety and efficacy in pediatric patients under 18 years of age have not been established; therefore, use of this medicine is not recommended.

Ingredients

Manufacturer
Dongkook Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy

  • Essential hypertension
View approved original text

This medication helps to lower blood pressure more effectively in patients with essential hypertension whose blood pressure is not adequately controlled despite combination therapy with amlodipine and olmesartan medoxomil. It plays an important role in regulating blood pressure by dilating blood vessels, thereby reducing the burden on the heart and blood vessels. Since inadequate blood pressure management can increase the risk of cardiovascular diseases, it is crucial to improve blood pressure regulation with this medication. Proper drug adjustments according to the patient's health condition can lead to stable blood pressure management. In conclusion, this medication is used for effective blood pressure control in essential hypertension.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. It is recommended that you take it at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dosage be adjusted using the individual ingredients (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose escalation schedule. (The content of each ingredient is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment For patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min), the maximum dose of this medicine is 20/5/12.5mg once daily. Monitoring potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. For patients with moderate hepatic impairment, the maximum dose of this medicine is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Elderly patients (65 years and older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. Blood pressure should be monitored closely and more frequently in elderly patients. Since experience with the use of this medicine in elderly patients, particularly those aged 75 years and older, is very limited, monitor very carefully when administering this medicine.

Child dose

Safety and efficacy in pediatric patients under 18 years of age have not been established; therefore, use of this medicine is not recommended.

Precautions

This drug can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to patients allergic to this drug or its components, those with specific heart, kidney, or liver diseases, pregnant or breastfeeding women, and patients with severe hypotension. Adequate observation and measures are necessary before treatment for patients with reduced blood volume or sodium, as hypotension may occur. Patients with decreased kidney function or kidney transplant recipients should have their kidney function periodically tested while taking this drug. It is recommended to avoid using this drug in patients with severe liver dysfunction or bile duct diseases. Elderly patients or those with certain cardiovascular diseases may have heightened sensitivity to the drug's effects and should be administered with caution. This drug lowers blood pressure and may cause dizziness or hypotension; caution is necessary when driving or operating dangerous machinery. There may be interactions with other medications taken alongside this one, so it is essential to inform the doctor or pharmacist of any other medications being used. In case of overdose, symptoms such as hypotension and palpitations may occur, and immediate medical attention should be sought. Safety and effectiveness of this medication in children have not been established, so it is not recommended for use in this population. Store this medication out of reach of children and avoid moisture and direct sunlight.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimuli, anxiety, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disorder, hypertonia, sensory loss, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremor, visual disturbances, decreased tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, alopecia, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pyoderma, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, frequent urination, acute renal failure, hematuria, dysuria, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption, intestinal vascular edema, altered consciousness, drug hypersensitivity, upper abdominal pain, decreased libido, inguinal edema, apathy, loss of consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, nosebleed, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Storing it this way maintains the drug's effectiveness and ensures its safe use.

Appearance and packaging

Appearance

White-orange round film-coated tablet

Package unit

28 Tablets (14 Tablets/PTP * 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.